Objective To observe the application effect of family-centered diversified extended services in treating retinopathy (ROP) of premature infants. Methods A total of 100 premature infants with ROP were selected and randomly divided into control group and observation group, with 50 cases in each group. The control group received routine nursing services, while the observation group received family-centered diversified extended services. The compliance of parents of infants, ocular parameters of infants, the 20-item Measure of Processes of Care (MPOC-20) score by parents and the Chinese version of Parenting Sense of Competence Scale (C-PSOC) score were compared between the two groups. Results The compliance of parents in the observation group was significantly better than that in the control group (P<0.05); one month after intervention, the decrease of intraocular pressure, the anterior chamber angle at 500 μm from the scleral spur (ACA500), central anterior chamber depth (CACD), and anterior chamber angle opening distance at 500 μm from the scleral spur (AOD500) in the observation group were significantly greater than those in the control group (P<0.05); after intervention, the MPOC-20 and C-PSOC scores of parents in the observation group were significantly higher than those in the control group (P<0.05). Conclusion Family-centered diversified extended services can improve the compliance of parents in participating in treatment and their satisfaction degree with nursing services, improve ocular conditions in ROP children, enhance parents′ sense of parenting competence, and have a positive effect on the prognostic recovery of ROP patients.

Levetiracetam (LEV) is the second generation of broad-spectrum antiepileptic drugs. Compared with other antiepileptic drugs, LEV has unique antiepileptic mechanism, good efficacy and tolerance, and its target is synaptic vesicle protein 2A. With the widespread use of LEV, more and more adverse reactions have been reported, especially mental related adverse reactions. This paper reviewed the research progress of LEV pharmacogenomics related targets, metabolism, adverse reaction related genetic variation and efficacy prediction, so as to provide decision-making for the application of LEV individualized treatment in clinical practice, improve the quality of life of epileptic patients and reduce the disease burden of patients with epilepsy.